Mangoceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
Mangoceuticals, Inc. filed a Form 8-K on October 4, 2023, reporting an event effective October 3, 2023. The filing concerns the appointment and compensation arrangement of Eugene M. Johnston, the Company’s Chief Financial Officer. Mangoceuticals is incorporated in Texas and its common stock trades on the Nasdaq Capital Market under the symbol MGRX.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
Material Changes
- Effective October 3, 2023, the Company entered into a 12-month consulting agreement with Eugene M. Johnston to serve as Chief Financial Officer and provide services as reasonably requested.
- Cash compensation is $2,000 per month.
- Mr. Johnston received 50,000 shares of common stock under the Company’s 2022 Equity Incentive Plan; the shares vested upon execution of the agreement.
- The Company will reimburse pre-approved expenses exceeding $500 and may provide discretionary equity bonuses or cash awards.
- Compensation may be increased by the Compensation Committee or Board of Directors without requiring an amended agreement.
Outlook, Risks, Contingencies, and Unusual Items
- The agreement may be terminated early by mutual approval, by a non-breaching party following an uncured breach, or by Mr. Johnston at any time for any reason.
- The agreement includes invention-assignment, indemnification, confidentiality, and non-solicitation provisions. Non-solicitation restrictions apply during the term and for 12 months afterward.
- The issuance of 50,000 vested shares creates an equity compensation obligation and potential dilution for existing shareholders; the filing does not state the shares’ market value.
- The filing provides no management guidance, business outlook, financial forecasts, or new operating risks.
Key Facts to Verify
- Review Exhibit 10.1 for the complete consulting agreement and termination provisions.
- Confirm the number, fair value, and accounting treatment of the 50,000 vested shares.
- Assess the aggregate cost of the 12-month arrangement, including monthly cash compensation, reimbursements, and any discretionary awards.
- Review subsequent filings for changes to Mr. Johnston’s role, compensation, or equity awards.